Roche's Genentech Granted Priority Review By FDA For Inavolisib, An Investigational Oral Therapy, In Combination With Palbociclib (Ibrance) And Fulvestrant

– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options –– Additional analyses of INAVO120 will be presented in an

BenzingaMay 29 00:08

Reported Earlier, Roche And Hitachi High-Tech Extend 46-Year Partnership For Diagnostic Testing Advances

Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for customers and patients worldwideUpcoming launches of t

BenzingaMay 28 02:27

Roche and Hitachi High-Tech Extend Their 46-year Partnership, Paving the Way for Further Breakthroughs in Diagnostic Testing

Yahoo FinanceMay 27 00:00

FDA Grants Breakthrough Therapy Designation to Roche's Inavolisib for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer With a PIK3CA Mutation

Yahoo FinanceMay 21 00:00

Viking Falls After Roche's Obesity Drug Data

Seeking AlphaMay 16 12:37

Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate

Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and typ

BenzingaMay 16 11:31